Biomarker-Driven Lung Cancer

>

Latest News

Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC

November 6th 2024

During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ lung cancer in the first article of a 2-part series.

First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC
First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC

November 4th 2024

Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced NSCLC
Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced NSCLC

October 24th 2024

Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare Cancers
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare Cancers

October 14th 2024

STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment
STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment

October 8th 2024

More News